Juvenile Dermatomyositis Clinical Trial
Official title:
Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis
The MYOCIT study aims to evaluate the efficacy and safety of baricitinib in association with corticosteroids in new-onset patients with juvenile dermatomyositis (JDM) in a phase II trial with the objective to obtain a better efficacy than the conventional combination methotrexate (MTX) and corticosteroids over the 24 week study period. Thus, the investigators hypothesize that baricitinib could be used as a first line treatment in all forms of DMJ, including the most severe one, with a good safety profile.
Juvenile dermatomyositis (JDM) is a rare and severe paediatric-onset idiopathic inflammatory myopathy, associated with significant morbidity and mortality. The combination of corticosteroids and methotrexate (MTX) is recommended in new-onset JDM according to one randomized trial. However, in this trial, treatment failures were reported in 13/46 (28%) patients and severe JDM, (cutaneous or gastrointestinal ulceration, interstitial pulmonary disease, cardiomyopathy) were not taken into account. These data emphasize the need for a more efficient first-line treatment. Considering: 1) the strong implication of type IFN-I in the pathophysiology of JDM 2) the report of the efficacy and safety of JAK inhibitors (JAKis) (baricitinb, tofacitinib) in about 50 refractory DM patients, and 9 JDM, a trial which evaluates the efficacy and safety of baricitinib in combination with corticosteroids in new-onset JDM is warranted. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05545839 -
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
|
N/A | |
| Recruiting |
NCT00059748 -
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
|
||
| Completed |
NCT00323960 -
Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis
|
Phase 3 | |
| Completed |
NCT02267005 -
The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis
|
N/A | |
| Completed |
NCT00106184 -
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
|
Phase 2 | |
| Completed |
NCT02245841 -
Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
|
Phase 4 | |
| Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
| Recruiting |
NCT01217320 -
Creatine Supplementation in Pediatric Rheumatology
|
N/A | |
| Completed |
NCT05509140 -
Clinical Analysis of Juvenile Dermatomyositis Patients
|
||
| Recruiting |
NCT01276470 -
Environmental Risk Factors for the Anti-synthetase Syndrome
|
||
| Recruiting |
NCT03433638 -
Juvenile Dermatomyositis
|
N/A | |
| Recruiting |
NCT03432455 -
Incidence and Prevalence of Juvenile Dermatomyositis
|
N/A | |
| Completed |
NCT00815282 -
Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
|
Phase 4 | |
| Completed |
NCT01697254 -
The CARRA Registry
|
N/A |